secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001654954-23-010419
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders
--------------------------------------------------------------------------------

- Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.
- Phase 2 trial of bremelanotide co-formulated with a PDE5i expected to start Q4 2023.
- Published data show synergy between bremelanotide and PDE5i via distinct mechanisms.
- Bremelanotide is the active agent in Vyleesi, approved for HSDD in women.
- Palatin successfully co-formulated bremelanotide with a PDE5i for single injection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/0001654954-23-010419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer